Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

You may be eligible if

• Patients with histologically confirmed locally advanced or metastatic NSCLC
• Presence of the ALK-fusion oncogene (ALK+) as determined using a validated testing platform
• Planned first or second-line treatment with crizotinib
• Signed and dated IRB-approved informed consent document
• Ability to read and understand English or French
• 18 years of age or older